Compare Domino's Pizza, Inc. (DPZ) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Domino's Pizza, Inc. vs Inovio Pharmaceuticals Inc — how do they compare? Domino's Pizza, Inc. trades at $309.36 (market cap $10.21B), while Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M). The key difference: Domino's Pizza, Inc. is far larger — about 91× Inovio Pharmaceuticals Inc's market cap, and Domino's Pizza, Inc. pays a 2.58% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Domino's Pizza, Inc. for 106 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| DPZ | INO | |
|---|---|---|
Market Cap | $10.21B | $112.19M |
Volume | 916,737 | 3,201,278 |
Sector | Consumer Cyclical | Health |
52-Week High | $438.42 | $2.60 |
52-Week Low | $282.89 | $0.66 |
Typical Hold Time | 106 Days | 43 Days |
Enterprise Value | $15.17B | $83.51M |
Dividend Yield | 2.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DPZ trades at $308.65, up 1.83% today, with a bullish technical signal but recent earnings misses. Revenue grew to $4.94B in 2025 with a net income margin of 11.86%, though the company carries significant debt. Analyst consensus is a Buy with a $373 price target, but news highlights concerns over dividend growth and store closures.
The outlook is mixed: strong profitability and analyst support suggest upside, but high debt and recent underperformance pose risks. Investors should weigh solid fundamentals against execution challenges and macroeconomic pressures on the restaurant sector.
INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.
Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
